Today, the U.S. Food and Drug Administration approved Gallium 68 PSMA-11 (Ga 68 PSMA-11) - the first drug for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA) ...
(UroToday.com) The 2026 ProsTIC annual meeting featured a PSMA imaging session and a presentation by Dr. Sidney Levy ...
Abstract outlining key findings from the Co-PSMA Investigator-Initiated Trial (IIT) has been released. The study was led by Prof Louise Emmett at St Vincent's Hospital Sydney, and the abstract was ...
The 2026 ProsTIC annual meeting featured a PSMA imaging session and a presentation by Dr. Daniel Moon discussing the PRIMARY ...
A newly established PSMA PET scoring system can successfully predict whether metastatic castration-resistant prostate cancer (mCRPC) patients will respond to treatment with 177 Lu-PSMA therapy.
Changes in planned disease management after piflufolastat F18 PET/CT in men with biochemically recurrent prostate cancer and low PSA levels: A secondary analysis of results from the CONDOR study. This ...
A new radioactive diagnostic agent for use in prostate cancer has been approved by the US Food and Drug Administration (FDA). The product, Gallium 68 PSMA-11 (Ga 68 PSMA-11), has been approved for ...
Rarely has a footnote garnered so much positive attention, but a reference in the newly updated prostate cancer guidelines from the National Comprehensive Cancer Network (NCCN) has prostate cancer ...
Pre-surgical 68Ga-PSMA-11 PET for biochemical recurrence risk assessment: A surrogate of pelvic lymph node dissection? Follow-up analysis of a multicenter prospective phase 3 imaging trial. This is an ...
Getty Images Ga 68 PSMA-11 PET can detect sites of local recurrence or metastasis in patients with biochemical evidence of recurrent prostate cancer. The FDA has approved gallium 68 PSMA-11 (Ga 68 ...
A nuclear medicine scan may locate prostate cancer recurrence after radical prostatectomy early after disease recurrence and could help guide salvage radiotherapy, according to new research from the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results